Acute Neurotoxicity Syndromes from Immunotherapy: Emergency and ICU Management
Seminars in Neurology · 12.11.2026
DOI: 10.1055/a-2979-8424 ↗Kurz gefasst
Fachartikel in der Zeitschrift Seminars in Neurology, erschienen am 12.11.2026. Verfasst von Caleb R S McEntire und 3 weiteren Autor:innen. Beteiligte Einrichtung: Massachusetts General Hospital, Department of Neurology, Massachusetts, United States, Boston.
Abstract (Originalsprache)
AbstractAdvances in cancer immunotherapy have transformed survival outcomes and driven widespread adoption of these treatments. However, as the population receiving immunotherapy has grown, neurologic complications have increasingly emerged, with rates of 1 to 3% among patients receiving immune checkpoint inhibitors and 26.9% among chimeric antigen receptor (CAR) T cell therapy recipients across all FDA-approved products. This review focuses on the early recognition and acute management of neurologic toxicities associated with immunotherapy, with particular emphasis on immune effector cell–associated neurotoxicity syndrome (ICANS) related to CD19 and BCMA-directed CAR T cell therapies. Herein we synthesize current understanding of clinical phenotypes and risk factors for severe neurotoxicity, and review evidence-based approaches to diagnostic evaluation, including neuroimaging, electroencephalography, and laboratory markers. Practical management strategies for severe cases are discussed, including corticosteroid initiation, cytokine-directed immunomodulatory therapies, exploratory therapies, and neurocritical supportive care for fulminant cerebral edema and status epilepticus. We address less common but high-risk neurologic complications associated with CAR T cell therapy beyond ICANS. Lastly, we touch upon key clinical findings and treatments for acute neurologic complications related to immune checkpoint inhibitors, bispecific T cell engagers, tumor-infiltrating lymphocyte therapy, and engineered T cell receptor therapies.
Autor:innen und Institutionen
- Massachusetts General Hospital, Department of Neurology, Massachusetts, United States, Boston.
- Harvard Medical School, Department of Neurology, Massachusetts, United States, Boston.
- University of Massachusetts T. H. Chan School of Medicine, Department of Neurology, Massachusetts, United States, Worcester.
- University of California Irvine, Department of Neurology, California, United States, Orange.
ORCID-Profile: Christine A Eckhardt
Zitieren
APA
McEntire, C. R. S., Tschoe, C., Manzano, G. S., & Eckhardt, C. A. (2026). Acute Neurotoxicity Syndromes from Immunotherapy: Emergency and ICU Management. Seminars in Neurology. https://doi.org/10.1055/a-2979-8424
Vancouver
McEntire CRS, Tschoe C, Manzano GS, Eckhardt CA. Acute Neurotoxicity Syndromes from Immunotherapy: Emergency and ICU Management. Seminars in Neurology. 2026. doi:10.1055/a-2979-8424
BibTeX
@article{McEntire2026,
author = {McEntire, Caleb R S and Tschoe, Christine and Manzano, Giovanna S and Eckhardt, Christine A},
title = {Acute Neurotoxicity Syndromes from Immunotherapy: Emergency and ICU Management},
journal = {Seminars in Neurology},
year = {2026},
doi = {10.1055/a-2979-8424}
}
EUVIMED